Share Price Rally 30% In A Week: Life Sciences Specialty Chemicals Company To Acquire 43.30% Stake In Bliss GVS Pharma At Rs 299 Per Share

On Monday, Indian equity benchmarks ended lower, with the benchmark Nifty 50 index declining 0.36 per cent to close at 23,299.05. Despite the weak market sentiment, Bliss GVS Pharma share price remained in focus after the company disclosed details of an open offer following a proposed acquisition by specialty chemicals manufacturer Anupam Rasayan India Ltd.

Anupam Rasayan To Acquire Controlling Stake

According to the detailed public statement filed with the stock exchanges, Anupam Rasayan India Limited has entered into a share purchase agreement dated May 23, 2026, to acquire 4,58,03,024 equity shares, representing 43.30 per cent of Bliss GVS Pharma's equity share capital, from existing promoters and certain public shareholders. The transaction is proposed to be executed at a price of Rs 299 per share.

The acquisition will result in a change in control of Bliss GVS Pharma, triggering a mandatory open offer under SEBI Takeover Regulations.

Rs 829 Crore Open Offer Announced

As part of the transaction, Anupam Rasayan has announced an open offer to acquire up to 2,77,26,848 equity shares, representing 26 per cent of the expanded voting share capital of Bliss GVS Pharma, from public shareholders at an offer price of Rs 299 per share.

The total consideration for the open offer works out to approximately Rs 829.03 crore, assuming full acceptance by eligible shareholders. The offer price is higher than the 60-day volume weighted average market price of Rs 247.55 per share calculated under SEBI regulations.

Transaction Value Exceeds Rs 1,369 Crore

The share purchase agreement involves the acquisition of a 43.30 per cent stake for a consideration of approximately Rs 1,369.51 crore. In addition, Anupam Rasayan has the option to acquire up to 51.81 lakh additional shares, representing 4.90 per cent of the company, under a call option arrangement with certain sellers.

Upon completion of the transaction and open offer, Anupam Rasayan is expected to become the promoter of Bliss GVS Pharma, while the existing promoter group will be reclassified as public shareholders, subject to regulatory requirements.

Financial Performance Of Bliss GVS Pharma

Bliss GVS Pharma reported consolidated revenue of Rs 1,000.64 crore in FY26, compared with Rs 846.22 crore in FY25. Net profit increased to Rs 134.73 crore from Rs 90.26 crore in the previous financial year.

The company reported earnings per share (EPS) of Rs 12.23 for FY26, while net worth stood at Rs 1,192.90 crore as of March 31, 2026.

About Bliss GVS Pharma

Bliss GVS Pharma Limited is engaged in the manufacturing of pharmaceutical products, including suppositories, pessaries, tablets, capsules and other specialty pharmaceutical formulations. The company operates in both domestic and international markets and is listed on the BSE and NSE.

Open Offer Timeline

The open offer is scheduled to open on July 16, 2026, and close on July 29, 2026. The last date for payment of consideration to shareholders whose shares are accepted under the offer is expected to be August 12, 2026.

Will the open offer and change in ownership drive the next phase of growth for Bliss GVS Pharma? Share your views below.
Disclaimer: The article is for informational purposes only and not investment advice.